Ahead of a Jan. 31 vote, Senate health committee chair Sen. Bernie Sanders on Thursday said he has the votes needed to subpoena the CEOs of Johnson & Johnson and Merck to testify on drug pricing.
Tag Archive for: Johnson & Johnson
An FDA advisory committee will meet to review J&J and Legend Biotech’s supplemental BLA for Carvykti for the treatment of relapsed or refractory multiple myeloma patients who have undergone at least one prior line of therapy.
Despite a new safety warning from the U.S. Food and Drug Administration, J&J still expects its cancer treatment to hit peak sales.
The agency stated that companies will be required to add a serious warning on the prescribing information for cancer therapies known as CAR-T, made by Gilead Sciences, Johnson & Johnson, Novartis and others.
Johnson & Johnson’s small molecule FGFR kinase inhibitor is now indicated for patients with susceptible FGFR3 mutations who progressed after at least one line of systemic therapy.
The pharma companies may be served with subpoenas to appear before the Senate health committee to explain why their products are much more expensive in the U.S. than in other countries, according to chairman Sen. Bernie Sanders.
Following the J.P. Morgan Healthcare Conference and other parallel meetings in San Francisco, it’s time to reflect on some of the significant deals secured last week.
Ambrx is developing therapies that belong to the class of drugs called antibody drug conjugates (ADC), which are described by researchers as “guided missiles” to target cancer cells and minimize damage to healthy tissue.
The ruling on Monday by U.S. District Judge Denise Cote in Manhattan federal court likely means the end of a consolidated mass tort litigation of about 500 lawsuits over the popular over-the-counter drug, unless plaintiffs get it reversed on appeal.
Several big-name drugmakers are weighing in on the opportunity in the weight-loss drugs market.
